

KDIGO CKD-MBD Implementation Summit

Tokyo 27-29 April 2018

Roundtable Session 1:

1. How can we improve CKD-MBD Monitoring Frequency and adherence to KDIGO Guidelines recommendations in your Country/Region for the different CKD stages?
Biochemical tests monitoring:
-Calcium Phosphate, PTH, Vitamin D testing, ALP
Imaging monitoring:
-Echo, Lat AXR, CT calcium score, DEXA scan
2. Is Fracture regarded an important complication in your CKD/ESKD patients? Would the new KDIGO 2017 guideline change your practice pattern by more routinely perform DEXA Scan in your CKD/ESKD patients?
3. Which recommendation statements in the KDIGO CKD-MBD 2009 and 2017 guideline update do you think should have implementation improved or promoted and what practice patterns in your Country/Region should change according to guideline recommendation? (aim of this question is to have consensus within the group on a few recommendation statements that should drive better implementation in this Region)

Eg. Target iPTH level, choice of dialysate calcium concentration, choice of phosphate binders, treatment for SHPT, parathyroidectomy

Roundtable Session 2:

1. What are the existing barriers and challenges for adoption or implementation of KDIGO CKD-MBD recommendations in your Country/Region?
 - Government and policy makers level
 - Hospital level
 - Nephrologists, physicians, healthcare team
 - Patient level
 - Drug availability issues
 - Cost and reimbursement issues
 - Strength of recommendation and level of evidence for the recommendation statement

Roundtable Session 3:

1. How could we improve KDIGO CKD-MBD guidelines implementation across the 8 Countries/Regions?
 - Government and policy makers level

- Hospital level
 - Nephrologists, physicians and healthcare team
 - Patient level
 - Drug availability issues
 - Cost and reimbursement issues
2. How do we monitor KDIGO CKD-MBD guideline implementation in your Country/Region?
 3. What can KDIGO do to help improve outcomes in relation to CKD-MBD management in your Country?